Dishman Pharmaceuticals and Chemicals has received Establishment Inspection Report from the US health regulator for three of its facilities.
Kunal Bothra, Head of Advisory at LKP recommends holding Dishman Pharmaceuticals and Chemicals. “The stock may go up to Rs 75-80 in next six-eight months,†he adds.
Ashu Madan, president of core client group at Religare Securities advised buying Dishman Pharma at current levels. In short-term, the stock can go up by 10-15 percent, feels Madan.
Sudarshan Sukhani of s2analytics.com said he would not buy Dishman Pharmaceuticals and Chemicals.
In CNBC-TV18's popular show Bull's Eye, Rajesh Agarwal, Eastern Financiers shares trading strategy of the day.
Dishman Pharmaceuticals and Chemicals' subsidiary Carbogen Amcis AG has acquired Creapharm Parenterals. In an interview to CNBC-TV18, VVS Murthy, chief financial officer of Dishman Pharma says, it is a small R&D formulation development company. The acquisition, he says, is funded trough internal accruals.
Drugmaker Dishman Pharmaceuticals and Chemicals reported a 31.8% dip in consolidated annual net profit on mounting raw material and operational costs.